Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Crizanlizumab-TMCA in Chronic Kidney Diseases: NCT04053764 Clinical Landscape Report 2026
16 October 2026
NCT04053764 clinical landscape for Chronic Kidney Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SubQ-8 in Hemophilia A: NCT04046848 Clinical Landscape Report 2026
16 October 2026
NCT04046848 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Viltolarsen in Muscular Dystrophy, Duchenne: NCT04060199 Clinical Landscape Report 2026
16 October 2026
NCT04060199 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nicotinamide in Acute Chest Syndrome: NCT04055818 Clinical Landscape Report 2026
16 October 2026
NCT04055818 clinical landscape for Acute Chest Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant coagulation factor VIII(Chia Tai-Tianqing) in Hemophilia A: NCT04061109 Clinical Landscape Report 2026
16 October 2026
NCT04061109 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Deferoxamine Mesylate in Chronic ulcer: NCT04058197 Clinical Landscape Report 2026
16 October 2026
NCT04058197 clinical landscape for Chronic ulcer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant coagulation factor VIII(Chia Tai-Tianqing) in Hemophilia A: NCT04060836 Clinical Landscape Report 2026
16 October 2026
NCT04060836 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bexotegrast in Idiopathic Pulmonary Fibrosis: NCT04072315 Clinical Landscape Report 2026
16 October 2026
NCT04072315 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Marzeptacog alfa in Hemophilia B: NCT04072237 Clinical Landscape Report 2026
16 October 2026
NCT04072237 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
18F-BMS-986327 in Idiopathic Pulmonary Fibrosis: NCT04069143 Clinical Landscape Report 2026
16 October 2026
NCT04069143 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mutated alpha-1 antitrypsi(ApcinteX) in Hemophilia B: NCT04073498 Clinical Landscape Report 2026
16 October 2026
NCT04073498 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Damoctocog Alfa Pegol in Hemophilia A: NCT04085458 Clinical Landscape Report 2026
16 October 2026
NCT04085458 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.